Modulating the Immune System
  • Svenska
Active Biotech
  • Home
  • About
    • Active Biotech in Brief
    • Board of Directors
    • Management
    • Business Concept
    • Corporate Governance
      • Corporate Governance Report 2017
      • Article of Association
      • Election Committee
      • General Meetings
      • Auditors
    • Partnerships
    • Career
  • Projects
    • Project Overview
    • ANYARA
    • Tasquinimod
    • SILC
    • Laquinimod
    • Paquinimod
    • Patents
    • Orphan Drug Designation
  • Investor
    • Investor
    • Financial Calendar
    • Financial Reports
      • Interim Reports
      • Annual Reports
    • Stock
    • Ownership
    • Official Documents
      • Rights Issue 2014
      • Rights Issue 2016
      • Rights Issue 2018
  • Media
    • Press Contact
    • Press Releases
      • Subscribe
    • News
    • Image Bank
  • Contact
Copyright © 2019 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.

Media

  • Press Contact
  • Press Releases
  • News
  • Image Bank

News

Active Biotech Year-end report January – December 2018

February 14, 2019

Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

February 11, 2019

Active Biotech has received an indicative bid for the property in Lund – the Board is positive

February 1, 2019

Active Biotech provides updated information about the company’s financial position

December 10, 2018

Interim report January – September 2018

November 15, 2018

New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018

November 8, 2018

<\span>

Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”

September 13, 2018

Active Biotech regains global rights to development and commercialization of laquinimod

September 5, 2018

Active Biotech AB – Interim Report January – June 2018

August 9, 2018

Active Biotech provides update on laquinimod in Huntington’s disease

July 31, 2018

Content

  • Home
  • About
  • Projects
  • Investor
  • Media
  • Contact

Postal Address

Active Biotech AB
P.O. Box 724
SE-220 07 Lund
Sweden

Visiting Address

Active Biotech AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

+46 46 19 20 00
info@activebiotech.com

LinkedIn

Copyright © 2019 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.
This site uses cookies.